Femasys (FEMY) 10-Q 10 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Document Transition Report	false
Entity File Number	001-40492
Entity Registrant Name	Femasys Inc.
Entity Central Index Key	0001339005
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3713499
Entity Address, Address Line One	3950 Johns Creek Court, Suite 100
Entity Address, City or Town	Suwanee
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30024
City Area Code	770
Local Phone Number	500-3910
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	FEMY
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		11,813,610

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 19,116,419	$ 24,783,029
Accounts receivable, net	113,960	84,258
Inventory, net	244,181	208,270
Other current assets	854,962	555,853
Total current assets	20,329,522	25,631,410
Property and equipment, at cost:
Leasehold improvements	1,195,637	1,155,332
Office equipment	99,344	99,344
Furniture and fixtures	424,947	424,947
Machinery and equipment	2,434,524	2,261,793
Construction in progress	461,735	379,713
Property and equipment, gross	4,616,187	4,321,129
Less accumulated depreciation	(2,985,367)	(2,722,117)
Net property and equipment	1,630,820	1,599,012
Long-term assets:
Lease right-of-use assets, net	486,926	665,747
Intangible assets, net of accumulated amortization	10,601	25,093
Other long-term assets	663,083	655,418
Total long-term assets	1,160,610	1,346,258
Total assets	23,120,952	28,576,680
Current liabilities:
Accounts payable	428,325	445,522
Accrued expenses	551,828	603,787
Clinical holdback - current portion	36,238	18,947
Note payable - current portion	417,841	181,123
Lease liabilities - current portion	394,518	406,674
Other - current	36,037	36,037
Total current liabilities	1,864,787	1,692,090
Long-term liabilities:
Clinical holdback - long-term portion	109,139	149,791
Lease liabilities - long-term portion	209,098	402,417
Total long-term liabilities	318,237	552,208
Total liabilities	2,183,024	2,244,298
Commitments and contingencies
Stockholders' equity:
Common stock, $.001 par, 200,000,000 authorized, 11,930,833 shares issued and 11,813,610 outstanding as of June 30, 2022; and 11,921,388 shares issued 11,804,165 outstanding as of December 31, 2021	11,931	11,921
Treasury stock, 117,223 shares	(60,000)	(60,000)
Warrants	567,972	702,492
Additional paid-in-capital	108,675,491	108,418,304
Accumulated deficit	(88,257,466)	(82,740,335)
Total stockholders' equity	20,937,928	26,332,382
Total liabilities and stockholders' equity	$ 23,120,952	$ 28,576,680

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Stockholders' equity:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	200,000,000	200,000,000
Common stock, issued (in shares)	11,930,833	11,921,388
Common stock, outstanding (in shares)	11,813,610	11,804,165
Treasury stock, shares (in shares)	117,223	117,223

Statements of Comprehensive Los

Statements of Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statements of Comprehensive Loss [Abstract]
Sales	$ 303,113	$ 326,006	$ 624,518	$ 655,781
Cost of sales	102,353	107,627	225,028	200,669
Gross margin	200,760	218,379	399,490	455,112
Operating expenses:
Research and development	1,472,924	894,868	2,893,987	1,889,890
Sales and marketing	63,177	21,828	132,040	44,647
General and administrative	1,181,938	1,051,399	2,629,293	1,943,386
Depreciation and amortization	142,684	151,359	286,883	304,812
Total operating expenses	2,860,723	2,119,454	5,942,203	4,182,735
Loss from operations	(2,659,963)	(1,901,075)	(5,542,713)	(3,727,623)
Other income (expense):
Interest income, net	26,745	144	29,199	308
Other income	0	821,515	0	821,515
Interest expense	(883)	(3,643)	(3,617)	(7,491)
Other income, net	25,862	818,016	25,582	814,332
Net loss	(2,634,101)	(1,083,059)	(5,517,131)	(2,913,291)
Net loss attributable to common stockholders, basic (in dollars per share)	(2,634,101)	(1,083,059)	(5,517,131)	(2,913,291)
Net loss attributable to common stockholders, diluted (in dollars per share)	$ (2,634,101)	$ (1,083,059)	$ (5,517,131)	$ (2,913,291)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.22)	$ (0.52)	$ (0.47)	$ (1.89)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.22)	$ (0.52)	$ (0.47)	$ (1.89)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	11,812,988	2,076,516	11,808,601	1,538,780
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	11,812,988	2,076,516	11,808,601	1,538,780

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Treasury Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member] Series B and Series C Redeemable Convertible Preferred Stock [Member]	Warrants [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2020				$ 55,343,686
Balance (in shares) at Dec. 31, 2020				55,835,833
Increase (Decrease) in Temporary Equity [Roll Forward]
Share-based compensation expense				$ 0
Automatic conversion of preferred stock in connection with IPO				$ (55,343,686)
Automatic conversion of preferred stock in connection with IPO (in shares)				(55,835,833)
Net loss				$ 0
Balance at Jun. 30, 2021				$ 0
Balance (in shares) at Jun. 30, 2021				0
Balance at Dec. 31, 2020	$ 1,110	$ (60,000)	$ 17,211		$ 702,492	$ 22,725,949	$ (75,202,490)	$ (51,815,728)
Balance (in shares) at Dec. 31, 2020	1,110,347	117,223	17,210,609
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for cash upon exercise of options	$ 40	$ 0	$ 0		0	112,105	0	112,145
Issuance of common stock for cash upon exercise of options (in shares)	40,253	0	0
Issuance of common stock in connection with IPO, net	$ 2,650	$ 0	$ 0		0	30,019,707	0	30,022,357
Issuance of common stock in connection with IPO, net (in shares)	2,650,000	0	0
Automatic conversion of preferred stock in connection with IPO	$ 8,116	$ 0	$ (17,211)		0	55,352,781	0	55,343,686
Automatic conversion of preferred stock in connection with IPO (in shares)	8,116,343	0	(17,210,609)
Share-based compensation expense	$ 0	$ 0	$ 0		0	130,536	0	130,536
Net loss	0	0	0		0	0	(2,913,291)	(2,913,291)
Balance at Jun. 30, 2021	$ 11,916	$ (60,000)	$ 0		702,492	108,341,078	(78,115,781)	30,879,705
Balance (in shares) at Jun. 30, 2021	11,916,943	117,223	0
Balance at Mar. 31, 2021				$ 55,343,686
Balance (in shares) at Mar. 31, 2021				55,835,833
Increase (Decrease) in Temporary Equity [Roll Forward]
Share-based compensation expense				$ 0
Automatic conversion of preferred stock in connection with IPO				$ (55,343,686)
Automatic conversion of preferred stock in connection with IPO (in shares)				(55,835,833)
Net loss				$ 0
Balance at Jun. 30, 2021				$ 0
Balance (in shares) at Jun. 30, 2021				0
Balance at Mar. 31, 2021	$ 1,112	$ (60,000)	$ 17,211		702,492	22,808,487	(77,032,722)	(53,563,420)
Balance (in shares) at Mar. 31, 2021	1,112,431	117,223	17,210,609
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock for cash upon exercise of options	$ 38	$ 0	$ 0		0	102,057	0	102,095
Issuance of common stock for cash upon exercise of options (in shares)	38,169	0	0
Issuance of common stock in connection with IPO, net	$ 2,650	$ 0	$ 0		0	30,019,707	0	30,022,357
Issuance of common stock in connection with IPO, net (in shares)	2,650,000	0	0
Automatic conversion of preferred stock in connection with IPO	$ 8,116	$ 0	$ (17,211)		0	55,352,781	0	55,343,686
Automatic conversion of preferred stock in connection with IPO (in shares)	8,116,343	0	(17,210,609)
Share-based compensation expense	$ 0	$ 0	$ 0		0	58,046	0	58,046
Net loss	0	0	0		0	0	(1,083,059)	(1,083,059)
Balance at Jun. 30, 2021	$ 11,916	$ (60,000)	$ 0		702,492	108,341,078	(78,115,781)	30,879,705
Balance (in shares) at Jun. 30, 2021	11,916,943	117,223	0
Balance at Dec. 31, 2021	$ 11,921	$ (60,000)			702,492	108,418,304	(82,740,335)	26,332,382
Balance (in shares) at Dec. 31, 2021	11,921,388	117,223
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expiration of warrant					(134,520)	134,520		0
Issuance of common stock for cash upon exercise of options	$ 10	$ 0			0	16,141	0	16,151
Issuance of common stock for cash upon exercise of options (in shares)	9,445	0
Share-based compensation expense	$ 0	$ 0			0	106,526	0	106,526
Net loss	0	0			0	0	(5,517,131)	(5,517,131)
Balance at Jun. 30, 2022	$ 11,931	$ (60,000)			567,972	108,675,491	(88,257,466)	20,937,928
Balance (in shares) at Jun. 30, 2022	11,930,833	117,223
Balance at Mar. 31, 2022	$ 11,921	$ (60,000)			702,492	108,462,663	(85,623,365)	23,493,711
Balance (in shares) at Mar. 31, 2022	11,921,388	117,223
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expiration of warrant					(134,520)	134,520		0
Issuance of common stock for cash upon exercise of options	$ 10	$ 0			0	16,141	0	16,151
Issuance of common stock for cash upon exercise of options (in shares)	9,445	0
Share-based compensation expense	$ 0	$ 0			0	62,167	0	62,167
Net loss	0	0			0	0	(2,634,101)	(2,634,101)
Balance at Jun. 30, 2022	$ 11,931	$ (60,000)			$ 567,972	$ 108,675,491	$ (88,257,466)	$ 20,937,928
Balance (in shares) at Jun. 30, 2022	11,930,833	117,223

Statements of Cash Flows

Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (5,517,131)	$ (2,913,291)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	272,391	281,928
Amortization	14,492	22,884
Amortization of right-of-use assets	169,680	193,290
Share-based compensation expense	106,526	130,536
Loan and accrued interest forgiveness on note payable	0	(821,515)
Inventory reserve	2,900	0
Changes in operating assets and liabilities:
Accounts receivable	(29,702)	(33,047)
Inventory	(38,811)	(15,501)
Other assets	255,271	329,461
Accounts payable	(74,957)	165,789
Accrued expenses and other	(76,959)	(1,017,803)
Lease liabilities	(194,235)	(210,045)
Other liabilities	(23,361)	5,933
Net cash used in operating activities	(5,133,896)	(3,881,381)
Cash flows from investing activities:
Purchases of property and equipment	(295,058)	(12,512)
Net cash used in investing activities	(295,058)	(12,512)
Cash flows from financing activities:
Proceeds from issuance of common stock	16,151	31,725,645
Payments of deferred offering costs	(13,905)	(1,243,960)
Repayment of note payable	(228,662)	(40,980)
Payments under lease obligations	(11,240)	(10,170)
Net cash (used in) provided by in financing activities	(237,656)	30,430,535
Net change in cash and cash equivalents	(5,666,610)	26,536,642
Cash and cash equivalents:
Beginning of period	24,783,029	3,322,226
End of period	19,116,419	29,858,868
Cash paid for:
Interest	3,617	4,130
Income taxes	800	800
Non-cash financing activities:
Prepaid insurance financed with promissory notes	417,841	470,556
Deferred offering costs included in accounts payable and accrued expenses	82,760	334,683
Conversion of convertible preferred stock to common stock	$ 0	$ 55,360,897

Organization, Nature of Busines

Organization, Nature of Business, and Liquidity	6 Months Ended
	Jun. 30, 2022
Organization, Nature of Business, and Liquidity [Abstract]
Organization, Nature of Business, and Liquidity	(1) Organization, Nature of Business, and Liquidity Organization and Nature of Business Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. Our mission is to provide women worldwide with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The Company currently operates as one segment and is primarily focused on servicing the reproductive health needs for those seeking permanent birth control or solutions for infertility issues. F emasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing. FemBloc® (FemBloc), the Company’s solution for permanent birth control, is based on the Company’s non-surgical platform technology and is presently completing a validation study under an approved Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA). FemaSeed ® Basis of Presentation The Company has prepared the accompanying financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2021 included in our Annual Report on Form 10K filed with the SEC on March 24, 2022 (the Annual Report). In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to mak e estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock options, warrants, useful lives of property and equipment, intangible assets, and the pre-initial public offering (IPO) Liquidity As of June 30, 2022, the Company has cash and cash equivalents of $19,116,419. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue from the sale of FemVue to support the Company’s research and development activities, largely in connection with FemBloc and FemaSeed. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted. For the six months ended June 30, 2022, the Company generated a net loss of $5,517,131. The Company expects such losses to increase over the next few years as the Company advances FemBloc and FemaSeed through clinical development until FDA approval is received and the products are available to be marketed. The Company believes that its cash and cash equivalents as of June 30, 2022 will be sufficient to fund our ongoing operations at least 12 months from the date of filing these financial statements. Recently Issued Accounting Pronouncements – Recently Adopted On January 1, 2021, the Company adopted Accounting Standards Update (ASU) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Recently Issued Accounting Pronouncements – Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses Measurement of Credit Losses on Financial Instruments No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

Cash and Cash Equivalents

Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	(2) Cash and Cash Equivalents As of June 30, 2022 and December 31, 2021, money market funds included in cash and cash equivalents on the balance sheets were $18,733,783 and $24,388,443, respectively, which represent level 1 within the fair value hierarchy where there are quoted prices in active markets for identical assets.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2022
Inventories [Abstract]
Inventories	(3) Inventories Inventory stated at cost, net of reserve, consisted of the following: June 30, 2022 December 31, 2021 Materials $ 137,490 111,531 Work in progress 98,403 12,795 Finished goods 8,288 83,944 Inventory, net $ 244,181 208,270 The FemVue reserve for slow moving, obsolete, or unusable inventories was as of June 30, 2022 and December 31, 2021, respectively.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2022
Accrued Expenses [Abstract]
Accrued Expenses	(4) Accrued Expenses Accrued expenses consisted of the following: June 30, 2022 December 31, 2021 Clinical trial costs $ 315,027 301,730 Compensation costs 132,888 98,272 Franchise taxes — 103,020 Other 103,913 100,765 Accrued expenses $ 551,828 603,787

Clinical Holdback

Clinical Holdback	6 Months Ended
	Jun. 30, 2022
Clinical Holdback [Abstract]
Clinical Holdback	(5) Clinical Holdback The following table shows the activity within the clinical holdback liability accounts for the six months ended June 30, 2022: Balance at December 31, 2021 $ 168,738 Clinical holdback retained 10,660 Clinical holdback paid (34,021 ) Balance at June 30 2022 $ 145,377 Less: clinical holdback - current portion (36,238 ) Clinical holdback - long-term portion $ 109,139

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2022
Revenue Recognition [Abstract]
Revenue Recognition	(6) Revenue Recognition Revenue is recognized upon shipment of our goods based upon contractually stated pricing at standard payment terms ranging from 30 to 60 days. All revenue is recognized point in time and no revenue is recognized over time. For the three and six months ended June 30, 2022 and 2021, there was no revenue recognized from performance obligations satisfied or partially satisfied in prior periods, nor were there any unsatisfied performance obligations as of June 30, 2022 or 2021. The majority of products sold directly to U.S customers are shipped via common carrier, and the customer pays for shipping and handling and assumes control Free on Board (FOB) shipping point. Products shipped to our international distributors are in accordance with their respective agreements; however, the shipping terms are generally EX-Works, reflecting that control is assumed by the distributor at the shipping point. Returns are only accepted with prior authorization from the Company. Items to be returned must be in original unopened cartons and are subject to a 30% restocking fee. Throughout the periods presented, the Company has not had a history of significant returns. The following table summarizes our FemVue sales by geographic region as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Primary geographical markets U.S. $ 303,113 268,019 566,473 539,749 International — 57,987 58,045 116,032 Total $ 303,113 326,006 624,518 655,781

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies [Abstract]
Commitments and Contingencies	(7) Commitments and Contingencies Legal Claims Occasionally, the Company may be a party to legal claims or proceedings of which the outcomes are subject to significant uncertainty. In accordance with Accounting Standards Codification Contingencies The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The Company entered into employment agreements with its officers, which provides for indemnification protection in the executive’s capacity as an officer for actions taken within the scope of employment. The maximum amount of potential future indemnification is unlimited; however, the Company has obtained director and officer insurance that limits its exposure. The Company believes the fair value for these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations as of June 30, 2022 and December 31, 2021.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2022
Notes Payable [Abstract]
Notes Payable	(8) Notes Payable AFCO Credit Corporation (AFCO) In June 2022, the Company executed a promissory note with AFCO to finance certain insurance premiums totaling $465,380, requiring the Company to pay $47,539 in a down payment and make monthly installment payments. The annual interest rate is 5.71% and the monthly installment is $47,539, which represents principal and interest. As of June 30, 2022 and December 31, 2021, the principal balance on the AFCO notes was $417,841 and $181,123, respectively and is included in Notes payable – current portion in the accompanying balance sheets. Interest expense in connection with the AFCO promissory notes was $86 and $946 for the three months ended June 30, 2022 and 2021, respectively ; and interest expense was $1,882 and $1,324 for the six months ended June 30, 2022 and 2021

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock and Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Redeemable Convertible Preferred Stock and Stockholders' Equity [Abstract]
Redeemable Convertible Preferred Stock and Stockholders' Equity	(9) Redeemable Convertible Preferred Stock and Stockholders’ Equity In June 2021, the Company issued 2,650,000 shares of common stock in connection with the Company’s IPO of its common stock at $13.00 per share. Net proceeds to the Company, after deducting underwriting discounts, commissions, and legal expenses, was $31,613,500. Offering costs incurred by the company were $2,016,143 , which include legal expenses incurred and paid by our underwriters of $425,000. The Company filed an eleventh amended and restated certificate of incorporation (the Amended and Restated Certificate) with the Secretary of State of the State of Delaware in connection with the completion of the IPO on June 22, 2021. The Amended and Restated Certificate amends and restates the Company’s existing certificate of incorporation in its entirety to, among other things: (i) authorize 200,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock (Series A, B and C); and (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series. As of June 30, 2022, the Company had 11,813,610 shares of common stock outstanding, and no dividends have been declared or paid.

Equity Incentive Plans

Equity Incentive Plans	6 Months Ended
	Jun. 30, 2022
Equity Incentive Plans [Abstract]
Equity Incentive Plans	(10) Equity Incentive Plans Stock-Based Awards (a) Stock Option Plans In June 2021, in connection with the IPO, our 2021 Equity Incentive Plan (2021 Plan) became effective, which was adopted by our Board of Directors in February 2021 and our stockholders approved the 2021 Plan in March 2021. The 2021 Plan is administered by our compensation committee. Upon the effectiveness of the 2021 Plan, no new grants will be awarded under our 2015 Stock-Based Incentive Compensation Plan. As of June 30, 2022, the total number of shares of common stock reserved for future awards under the 2021 Plan is 1,313,137. Activity under the stock option plans was as follows: Number of options Weighted average exercise price Weighted average remaining contracted term in years Aggregate intrinsic value Outstanding at December 31, 2021 689,995 $ 3.58 $ 683,531 Granted 270,170 6.71 Expired (3,334 ) 27.00 Forfeited (834 ) 6.12 Outstanding at March 31, 2022 955,997 $ 4.38 6.47 $ 125,279 Granted 51,000 1.50 Exercised (9,445 ) 1.71 Expired (278 ) 27.00 Forfeited (46,668 ) 3.27 Outstanding at June 30, 2022 950,606 $ 4.30 6.55 $ 181,745 Vested and exercisable at June 30, 2022 476,941 $ 3.71 5.08 $ 57,557 Options granted under our 2021 Plan for the six months ended June 30, 2022 to employees and nonemployees were 253,170 and 68,000, respectively, and the weighted average exercise prices were $6.96 and $1.88, respectively. Included in awards granted to employees are 140,000 of performance based options that vest on achieving certain clinical related milestones. The weighted-average weighted-average Employee Nonemployee Expected term (in years) 6.47 5.63 Risk‑free interest rate 1.74 % 2.67 % Dividend yield — % — % Expected volatility 107.23 % 109.67 % The intrinsic value of options exercised during the six months ended June 30, 2022 was $3,306. The intrinsic value represents the dollar value of the exercised stock options whereby the fair market value of the underlying common stock exceeded the exercise price of the stock option as of the exercise date (b) Inducement Grant On February 28, 2022, the Company awarded, outside the 2021 Plan, our Chief Financial Officer a stock option grant for the right to purchase 100,000 shares of common stock at an exercise price of $2.97 per share (inducement grant), which was approved by the Compensation Committee. The inducement grant will vest in equal installments over four years provided the employee remains employed by the Company on the vesting date. The fair value of the inducement grant was $2.46 and was estimated using the following assumptions: Inducement Expected term (in years) 6.25 Risk‑free interest rate 1.76 % Dividend yield — % Expected volatility 106.76 % As of June 30, 2022, 100,000 shares are outstanding, and none are exercisable. (c) Share-Based Compensation Expense The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying statement of comprehensive loss: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 33,436 29,205 62,575 64,702 Sales and marketing 1,216 936 2,342 1,861 General and administrative 27,515 27,905 41,609 63,973 Total share-based compensation expense $ 62,167 58,046 106,526 130,536 As June 30, 2022, the remaining share-based compensation expense that is expected to be recognized in future periods for employees and nonemployees is $1,123,502, which includes $463,311 of compensation expense to be recognized upon achieving certain performance conditions. For service based awards, the $660,191 of unrecognized expense is expected to be recognized over a weighted average period of 3.0 years. (d) Employee Stock Purchase Plan In June 2021, in connection with the IPO, our Employee Stock Purchase Plan (ESPP) became effective which was adopted by our Board of Directors in February 2021 and our stockholders approved the 2021 ESPP Plan in March 2021. The ESPP is administered by our compensation committee. As of June 30, 2022, the total number of shares of common stock reserved for future awards under the ESPP Plan is 284,707, and no shares of our common stock have been purchased under the ESPP.

Net Loss per Share Attributable

Net Loss per Share Attributable to Common Stockholders	6 Months Ended
	Jun. 30, 2022
Net Loss per Share Attributable to Common Stockholders [Abstract]
Net Loss per Share Attributable to Common Stockholders	(11) Net Loss per Share Attributable to Common Stockholders The following ta ble sets forth the computation of t Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Net loss attributable to common stockholders, basic & diluted $ (2,634,101 ) (1,083,059 ) (5,517,131 ) (2,913,291 ) Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted 11,812,988 2,076,516 11,808,601 1,538,780 Net loss per share attributable to common stockholders, basic and diluted $ (0.22 ) (0.52 ) (0.47 ) (1.89 ) The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Options to purchase common stock 1,050,606 699,636 1,050,606 699,636 Warrants to purchase to common stock 233,460 244,572 233,460 244,572 Total potential shares 1,284,066 944,208 1,284,066 944,208

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	(12) Subsequent Events On July 1, 2022, the Company entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler” or the “Sales Agent”) establishing an “at-the-market” facility, pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to $8,800,000 from time to time through the Sales Agent. As of August 10, 2022, no shares had been sold under the Equity Distribution Agreement.

Organization, Nature of Busin_2

Organization, Nature of Business, and Liquidity (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Nature of Business, and Liquidity [Abstract]
Organization and Nature of Business	Organization and Nature of Business Femasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. The Company is a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. Our mission is to provide women worldwide with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The Company currently operates as one segment and is primarily focused on servicing the reproductive health needs for those seeking permanent birth control or solutions for infertility issues. F emasys has an expansive intellectual property portfolio which covers both design and utility patents in the U.S. and significant ex-U.S. markets for each product initiative. Femasys has taken concepts internally conceived and protected through development, including domestic and foreign regulatory approvals, and production, through in-house manufacturing. FemBloc® (FemBloc), the Company’s solution for permanent birth control, is based on the Company’s non-surgical platform technology and is presently completing a validation study under an approved Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA). FemaSeed ®
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to these rules and regulations. These financial statements should be read in conjunction with the Company’s audited financial statements and footnotes related thereto for the year ended December 31, 2021 included in our Annual Report on Form 10K filed with the SEC on March 24, 2022 (the Annual Report). In the opinion of management, the unaudited financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows at the dates for periods presented. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to mak e estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock options, warrants, useful lives of property and equipment, intangible assets, and the pre-initial public offering (IPO)
Liquidity	Liquidity As of June 30, 2022, the Company has cash and cash equivalents of $19,116,419. The Company plans to finance its operations and development needs with its existing cash and cash equivalents, additional equity and/or debt financing arrangements, and revenue from the sale of FemVue to support the Company’s research and development activities, largely in connection with FemBloc and FemaSeed. There can be no assurance that the Company will be able to obtain additional financing on terms acceptable to the Company, on a timely basis, or at all. If the Company is not able to obtain sufficient funds on acceptable terms when needed, the Company’s business, results of operations, and financial condition could be materially adversely impacted. For the six months ended June 30, 2022, the Company generated a net loss of $5,517,131. The Company expects such losses to increase over the next few years as the Company advances FemBloc and FemaSeed through clinical development until FDA approval is received and the products are available to be marketed. The Company believes that its cash and cash equivalents as of June 30, 2022 will be sufficient to fund our ongoing operations at least 12 months from the date of filing these financial statements.
Recently Issued Accounting Pronouncements Adopted and Not Yet Adopted	Recently Issued Accounting Pronouncements – Recently Adopted On January 1, 2021, the Company adopted Accounting Standards Update (ASU) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Recently Issued Accounting Pronouncements – Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses Measurement of Credit Losses on Financial Instruments No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s financial statements.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2022
Inventories [Abstract]
Inventory Stated at Cost, Net of Reserve	Inventory stated at cost, net of reserve, consisted of the following: June 30, 2022 December 31, 2021 Materials $ 137,490 111,531 Work in progress 98,403 12,795 Finished goods 8,288 83,944 Inventory, net $ 244,181 208,270

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Accrued Expenses [Abstract]
Accrued Expenses	Accrued expenses consisted of the following: June 30, 2022 December 31, 2021 Clinical trial costs $ 315,027 301,730 Compensation costs 132,888 98,272 Franchise taxes — 103,020 Other 103,913 100,765 Accrued expenses $ 551,828 603,787

Clinical Holdback (Tables)

Clinical Holdback (Tables)	6 Months Ended
	Jun. 30, 2022
Clinical Holdback [Abstract]
Clinical Holdback Liability	The following table shows the activity within the clinical holdback liability accounts for the six months ended June 30, 2022: Balance at December 31, 2021 $ 168,738 Clinical holdback retained 10,660 Clinical holdback paid (34,021 ) Balance at June 30 2022 $ 145,377 Less: clinical holdback - current portion (36,238 ) Clinical holdback - long-term portion $ 109,139

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue Recognition [Abstract]
Sales by Geographic Region	The following table summarizes our FemVue sales by geographic region as follows: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Primary geographical markets U.S. $ 303,113 268,019 566,473 539,749 International — 57,987 58,045 116,032 Total $ 303,113 326,006 624,518 655,781

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2022
Equity Incentive Plans [Abstract]
Stock Option Plan Activity	Activity under the stock option plans was as follows: Number of options Weighted average exercise price Weighted average remaining contracted term in years Aggregate intrinsic value Outstanding at December 31, 2021 689,995 $ 3.58 $ 683,531 Granted 270,170 6.71 Expired (3,334 ) 27.00 Forfeited (834 ) 6.12 Outstanding at March 31, 2022 955,997 $ 4.38 6.47 $ 125,279 Granted 51,000 1.50 Exercised (9,445 ) 1.71 Expired (278 ) 27.00 Forfeited (46,668 ) 3.27 Outstanding at June 30, 2022 950,606 $ 4.30 6.55 $ 181,745 Vested and exercisable at June 30, 2022 476,941 $ 3.71 5.08 $ 57,557
Estimated Using Assumptions	The weighted-average weighted-average Employee Nonemployee Expected term (in years) 6.47 5.63 Risk‑free interest rate 1.74 % 2.67 % Dividend yield — % — % Expected volatility 107.23 % 109.67 % The fair value of the inducement grant was $2.46 and was estimated using the following assumptions: Inducement Expected term (in years) 6.25 Risk‑free interest rate 1.76 % Dividend yield — % Expected volatility 106.76 %
Share-based Compensation Expense	The following table shows the share-based compensation expense related to vested stock option grants to employees and nonemployees by financial statement line item on the accompanying statement of comprehensive loss: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 33,436 29,205 62,575 64,702 Sales and marketing 1,216 936 2,342 1,861 General and administrative 27,515 27,905 41,609 63,973 Total share-based compensation expense $ 62,167 58,046 106,526 130,536

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Common Stockholders (Tables)	6 Months Ended
	Jun. 30, 2022
Net Loss per Share Attributable to Common Stockholders [Abstract]
Computation of Basic and Diluted Net Loss Per Share	The following ta ble sets forth the computation of t Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Net loss attributable to common stockholders, basic & diluted $ (2,634,101 ) (1,083,059 ) (5,517,131 ) (2,913,291 ) Weighted-average number of shares used in computing net loss per share attributable to common stockholders, basic and diluted 11,812,988 2,076,516 11,808,601 1,538,780 Net loss per share attributable to common stockholders, basic and diluted $ (0.22 ) (0.52 ) (0.47 ) (1.89 )
Computations of Diluted Weighted Average Shares Outstanding	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding because they would be anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Options to purchase common stock 1,050,606 699,636 1,050,606 699,636 Warrants to purchase to common stock 233,460 244,572 233,460 244,572 Total potential shares 1,284,066 944,208 1,284,066 944,208

Organization, Nature of Busin_3

Organization, Nature of Business, and Liquidity (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Segment	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Organization and Nature of Business [Abstract]
Number of operating segments | Segment			1
Liquidity [Abstract]
Cash and cash equivalents	$ 19,116,419		$ 19,116,419		$ 24,783,029
Net loss	$ (2,634,101)	$ (1,083,059)	$ (5,517,131)	$ (2,913,291)

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Level 1 [Member] | Money Market Funds [Member]
Assets, Fair Value Disclosure [Abstract]
Cash and cash equivalent	$ 18,733,783	$ 24,388,443

Inventories (Details)

Inventories (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Inventories [Abstract]
Materials	$ 137,490	$ 111,531
Work in progress	98,403	12,795
Finished goods	8,288	83,944
Inventory, net	244,181	208,270
Reserve for expired inventory	$ 1,292	$ 850

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Accrued Expenses [Abstract]
Clinical trail costs	$ 315,027	$ 301,730
Compensation costs	132,888	98,272
Franchise taxes	0	103,020
Other	103,913	100,765
Accrued expenses	$ 551,828	$ 603,787

Clinical Holdback (Details)

Clinical Holdback (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Clinical Holdback Liability [Roll Forward]
Balance	$ 168,738
Clinical holdback retained	10,660
Clinical holdback paid	(34,021)
Balance	145,377
Less: clinical holdback - current portion	(36,238)	$ (18,947)
Clinical holdback - long-term portion	$ 109,139	$ 149,791

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue Recognition [Abstract]
Revenue recognized from performance obligations in prior periods	$ 0	$ 0	$ 0	$ 0
Percentage of restocking fee			30%
Primary Geographical Markets [Abstract]
Sales	303,113	326,006	$ 624,518	655,781
FemVue [Member]
Primary Geographical Markets [Abstract]
Sales	303,113	326,006	624,518	655,781
FemVue [Member] | U.S. [Member]
Primary Geographical Markets [Abstract]
Sales	303,113	268,019	566,473	539,749
FemVue [Member] | International [Member]
Primary Geographical Markets [Abstract]
Sales	$ 0	$ 57,987	$ 58,045	$ 116,032
Minimum [Member]
Revenue Recognition [Abstract]
Revenue recognition payment period term			30 days
Maximum [Member]
Revenue Recognition [Abstract]
Revenue recognition payment period term			60 days

Notes Payable (Details)

Notes Payable (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Notes Payable [Abstract]
Down payments				$ 228,662	$ 40,980
Note payable - current portion	$ 417,841	$ 417,841		$ 417,841		$ 181,123
Promissory Notes [Member] | AFCO Credit Corporation [Member]
Notes Payable [Abstract]
Proceeds to pay insurance premiums	465,380
Down payments	$ 47,539
Interest rate	5.71%	5.71%		5.71%
Frequency of installment payments				monthly
Monthly principal and interest payments	$ 47,539
Note payable - current portion	$ 417,841	$ 417,841		$ 417,841		$ 181,123
Interest expense on loan		$ 86	$ 946	$ 1,882	$ 1,324

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock and Stockholders' Equity (Details) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Stockholders Equity [Abstract]
Common stock, outstanding (in shares)			11,813,610		11,804,165
Dividends declared or paid			$ 0
IPO [Member]
Stockholders Equity [Abstract]
Shares issued and sold (in shares)	2,650,000
Share price (in dollars per share)	$ 13	$ 13		$ 13
Proceeds from issuance after deducting underwriting discounts, commissions, and legal expenses	$ 31,613,500
Deferred offering costs	2,016,143	$ 2,016,143		$ 2,016,143
Legal expenses incurred paid by underwriters	$ 425,000
Automatic conversion of preferred stock (in shares)	8,116,343
Common Stock [Member]
Stockholders Equity [Abstract]
Shares issued and sold (in shares)		2,650,000		2,650,000
Automatic conversion of preferred stock (in shares)		8,116,343		8,116,343
Number of shares authorized, for all classes of stock (in shares)			200,000,000
Preferred Stock [Member]
Stockholders Equity [Abstract]
Shares issued and sold (in shares)		0		0
Automatic conversion of preferred stock (in shares)		(17,210,609)		(17,210,609)
Number of shares authorized, for all classes of stock (in shares)			10,000,000

Equity Incentive Plans, Stock O

Equity Incentive Plans, Stock Option Plans (Details) - shares	1 Months Ended
	Jun. 30, 2021	Jun. 30, 2022
2015 Plan [Member]
Stock Option Plan [Abstract]
New grants awarded (in shares)	0
2021 Plan [Member]
Stock Option Plan [Abstract]
Common stock reserved for issuance (in shares)		1,313,137

Equity Incentive Plans, Stock_2

Equity Incentive Plans, Stock Option Plan, Activity (Details) - 2021 Employee Stock Purchase Plan [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Number of Options [Roll Forward]
Beginning balance (in shares)	955,997	689,995	689,995
Granted (in shares)	51,000	270,170
Exercised (in shares)	(9,445)
Expired (in shares)	(278)	(3,334)
Forfeited (in shares)	(46,668)	(834)
Ending balance (in shares)	950,606	955,997	950,606
Weighted Average Exercise Price [Abstract]
Beginning balance (in dollars per share)	$ 4.38	$ 3.58	$ 3.58
Granted (in dollars per share)	1.50	6.71
Exercised (in dollars per share)	1.71
Expired (in dollars per share)	27	27
Forfeited (in dollars per share)	3.27	6.12
Ending balance (in dollars per share)	$ 4.30	$ 4.38	$ 4.30
Option outstanding [Abstract]
Weighted average remaining contracted term in years	6 years 6 months 18 days	6 years 5 months 19 days
Aggregate intrinsic value	$ 181,745	$ 125,279	$ 181,745	$ 683,531
Options vested and exercisable [Abstract]
Options vested and exercisable, Number of option vested (in shares)	476,941		476,941
Options vested and exercisable, Exercise price (in dollars per share)	$ 3.71		$ 3.71
Options vested and exercisable, Weighted average remaining life years			5 years 29 days
Option vested, Aggregate intrinsic value	$ 57,557		$ 57,557
Estimated Fair Value Assumptions [Abstract]
Intrinsic value of options exercised			$ 3,306
Employee [Member]
Number of Options [Roll Forward]
Granted (in shares)			253,170
Weighted Average Exercise Price [Abstract]
Ending balance (in dollars per share)	$ 6.96		$ 6.96
Options vested and exercisable [Abstract]
Fair values of options granted (in dollars per share)			$ 2.34
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)			6 years 5 months 19 days
Risk free interest rate			1.74%
Dividend yield			0%
Expected volatility			107.23%
Employee [Member] | Performance Based Options [Member]
Number of Options [Roll Forward]
Granted (in shares)			140,000
Nonemployee [Member]
Number of Options [Roll Forward]
Granted (in shares)			68,000
Weighted Average Exercise Price [Abstract]
Ending balance (in dollars per share)	$ 1.88		$ 1.88
Options vested and exercisable [Abstract]
Fair values of options granted (in dollars per share)			$ 1.55
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)			5 years 7 months 17 days
Risk free interest rate			2.67%
Dividend yield			0%
Expected volatility			109.67%

Equity Incentive Plans, Inducem

Equity Incentive Plans, Inducement Grant and Valuation (Details) - Inducement Grant [Member] - $ / shares		6 Months Ended
	Feb. 28, 2022	Jun. 30, 2022
Inducement Grant [Abstract]
Granted (in shares)	100,000
Exercise price (in dollars per share)	$ 2.97
Vesting period		4 years
Fair values of options granted (in dollars per share)	$ 2.46
Estimated Fair Value Assumptions [Abstract]
Expected term (in years)		6 years 3 months
Risk free interest rate		1.76%
Dividend yield		0%
Expected volatility		106.76%
Shares outstanding (in shares)		100,000
Option exercisable (in shares)		0

Equity Incentive Plans, Share-B

Equity Incentive Plans, Share-Based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Expense [Abstract]
Share-based compensation expense	$ 62,167	$ 58,046	$ 106,526	$ 130,536
Share-based compensation expense expected to be recognized for employees and nonemployees	1,123,502		1,123,502
Compensation expense to be recognized upon achieving certain performance condition			463,311
Unrecognized expenses	660,191		$ 660,191
Weighted-average period over which unrecognized compensation is expected to be recognized			3 years
Research and Development [Member]
Share-based Compensation Expense [Abstract]
Share-based compensation expense	33,436	29,205	$ 62,575	64,702
Sales and Marketing [Member]
Share-based Compensation Expense [Abstract]
Share-based compensation expense	1,216	936	2,342	1,861
General and Administrative [Member]
Share-based Compensation Expense [Abstract]
Share-based compensation expense	$ 27,515	$ 27,905	$ 41,609	$ 63,973

Equity Incentive Plans, Employe

Equity Incentive Plans, Employee Stock Purchase Plan (Details) - 2021 Employee Stock Purchase Plan [Member]	Jun. 30, 2022 shares
Employee Stock Purchase Plan [Abstract]
Common stock reserved for issuance (in shares)	284,707
Common stock purchased (in shares)	0

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net Loss per Share Attributable to Common Stockholders [Abstract]
Net loss attributable to common stockholders, basic	$ (2,634,101)	$ (1,083,059)	$ (5,517,131)	$ (2,913,291)
Net loss attributable to common stockholders, diluted	$ (2,634,101)	$ (1,083,059)	$ (5,517,131)	$ (2,913,291)
Weighted average number of shares used in computing net loss per share attributable to common stockholders, basic (in shares)	11,812,988	2,076,516	11,808,601	1,538,780
Weighted average number of shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	11,812,988	2,076,516	11,808,601	1,538,780
Net loss per share attributable to common stockholders, basic (In dollars per share)	$ (0.22)	$ (0.52)	$ (0.47)	$ (1.89)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.22)	$ (0.52)	$ (0.47)	$ (1.89)
Weighted Average Number of Shares Outstanding [Abstract]
Options to purchase common stock (in shares)	1,050,606	699,636	1,050,606	699,636
Warrants to purchase to common stock (in shares)	233,460	244,572	233,460	244,572
Total potential shares (in shares)	1,284,066	944,208	1,284,066	944,208

Subsequent Events (Details)

Subsequent Events (Details) - Common Stock [Member] - USD ($)		3 Months Ended	6 Months Ended
	Aug. 10, 2022	Jun. 30, 2021	Jun. 30, 2021	Jul. 12, 2022
Subsequent Event [Abstract]
Common stock sold (in shares)		2,650,000	2,650,000
Subsequent Event [Member]
Subsequent Event [Abstract]
Authorized offering amount of securities				$ 8,800,000
Common stock sold (in shares)	0